

Place: Gaithersburg Marriott Washingtonian Center, 9751 Washington Blvd., Gaithersburg, MD 20878.

Contact Person: Anita T. Tandle, Ph.D., Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W248, Bethesda, MD 20892, 240-276-5085, tandlea@mail.nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel; NCI Program Project (P01) Review III.

Date: February 6–7, 2020.

Time: 8:00 a.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Bethesda North Marriott Hotel & Conference Center, Montgomery County Conference Center Facility, 5701 Marinelli Road, North Bethesda, MD 20852.

Contact Person: Jennifer C. Schiltz, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, Rockville, MD 20850, 240-276-5864, jennifer.schiltz@nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel; SEP 7: NCI Clinical and Translational R21 and Omnibus R03.

Date: February 12–13, 2020.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Robert Stephen Coyne, Ph.D., Scientific Review Officer, National Cancer Institute, NIH, Division of Extramural Activities, Special Review Branch, 9609 Medical Center Drive, Room 7W236, Rockville, MD 20850, 240-276-5120, coyners@mail.nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel; SEP-3: NCI Clinical and Translational R21 and Omnibus R03.

Date: February 13–14, 2020.

Time: 8:00 a.m. to 12:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Bethesda North Marriott Hotel & Conference Center, Montgomery County Conference Center Facility, 5701 Marinelli Road, North Bethesda, MD 20852.

Contact Person: Hasan Siddiqui, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W240, Rockville, MD 20850, 240-276-5122, hasan.siddiqui@nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel; TEP-1: SBIR Contract Review.

Date: February 19–20, 2020.

Time: 6:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate contract proposals.

Place: Marriott Bethesda North Hotel & Conference Center, 5701 Marinelli Road, Rockville, MD 20850.

Contact Person: Nadeem Khan, Ph.D., Scientific Review Officer, Research

Technology and Contract Review Branch, Division of Extramural Activities, 9609 Medical Center Drive, Room 7W260, National Cancer Institute, NIH, Bethesda, MD 20892-9745, 240-276-5856, nadeem.khan@nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel; NCI Research Specialist Award R50.

Date: February 27–28, 2020.

Time: 5:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD 20852.

Contact Person: Zhiqiang Zou, M.D., Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, 7W242, Bethesda, MD 20892, 240-276-6372, zouzhiq@mail.nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel; Transition to Independence SEP.

Date: March 10, 2020.

Time: 10:30 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W602, Rockville, MD 20850 (Telephone Conference Call).

Contact Person: Delia Tang, M.D., Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W602, Bethesda, MD 20892, 240-276-6456, tangd@mail.nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel; Quantitative Imaging Methods and Resources (UG3/UH3, U24).

Date: March 13, 2020.

Time: 11:00 a.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 6W030, Rockville, MD 20850 (Telephone Conference Call).

Contact Person: Saejeong J. Kim, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W640, Rockville, MD 20850, 240-276-7684, saejeong.kim@nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel; HIV-Associated Malignancy Research.

Date: March 26–27, 2020.

Time: 5:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Marriott Bethesda North Hotel & Conference Center, 5701 Marinelli Road, Rockville, MD 20852.

Contact Person: Nadeem Khan, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, 9609 Medical Center Drive, Room 7W260, National Cancer Institute, NIH, Bethesda, MD 20892-9745, 240-276-5856, nadeem.khan@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: December 10, 2019.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-27003 Filed 12-13-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of an Exclusive Patent License: The Development of Siglec-6-Specific Chimeric Antigen Receptor (CAR) for the Treatment Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), and Other Forms of Acute and Chronic B- and T-Cell Leukemia and Lymphoma

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the **SUPPLEMENTARY INFORMATION** section of this notice to T-CURX GmbH (T-CURX), located in Würzburg, Germany.

DATES: Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before December 31, 2019 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: Aritee Dhal, Ph.D., Technology Transfer Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM 3W610, MSC 9702, Bethesda, MD 20892-9702, (for business mail), Rockville, MD 20850-9702, Telephone: (240) 276-6154; Facsimile: (240) 276-5504; Email: aritee.dhal@nih.gov.

SUPPLEMENTARY INFORMATION:

Intellectual Property

U.S. Provisional Patent Application 61/178,688 entitled "A Panel Of Fully

Human Monoclonal Antibodies To The Same Epitope Of An Unknown Cell Surface Antigen Expressed In B-cell Lymphocytic Leukemia (B-CLL)” [HHS Ref. E-163-2009-0-US-01], PCT Patent Application PCT/US2010/034491 entitled “B-cell Surface Reactive Antibodies” [HHS Ref. E-163-2009-0-PCT-02], and United States Patent 8,877,199, entitled “B-cell Surface Reactive Antibodies” [HHS Ref. E-163-2009-0-US-03].

The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.

The prospective exclusive license territory may be worldwide and the field of use may be limited to

The development, production, and commercialization of a Siglec-6-specific chimeric antigen receptor (CAR) based immunotherapy using autologous (meaning one individual is both the donor and recipient) T cells modified by virus-free Sleeping Beauty (SB)-based gene transposition compromising of at least:

- a. A single antigen specificity; and
- b. comprising at least:
 - i. The complementary determining region (CDR) sequences of the Siglec-6 antibody known as JML-1, and
 - ii. a CD3ζ activation module and either a CD28 or a 4-1BB co-stimulation moiety.

for the treatment of acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and other forms of acute and chronic B- and T-cell leukemia and lymphoma.

The licensed field of use excludes any (a) non-specified immunoconjugates, including, but not limited to, antibody drug conjugates and immunotoxins and (b) unconjugated antibodies.

This technology discloses monoclonal antibodies that are specific for the cell surface domain of Siglec-6. The antibodies can potentially be used for the treatment of acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and other forms of acute and chronic B- and T-cell leukemia and lymphoma cells. In the subject situation, the antibodies can be used in a CAR, leading to the selective destruction of the cancerous cells.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not

be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: December 5, 2019.

Richard U. Rodriguez,

Associate Director, Technology Transfer Center, National Cancer Institute.

[FR Doc. 2019-27002 Filed 12-13-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director, National Institutes of Health; Notice of Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the meetings of the Council of Councils.

The meetings will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The open session will be videocast and can be accessed from the NIH Videocasting and Podcasting website (<http://videocast.nih.gov>).

A portion of the meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4), and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Council of Councils.

Open: January 24, 2020.

Time: 8:15 a.m. to 12:10 p.m.

Agenda: Call to Order and Introductions; Announcements and Updates; Scientific Talks; NIH Program Updates.

Place: National Institutes of Health, John E. Porter Neuroscience Research Center, Building 35A, Rooms 620/630, 35 Convent Drive, Bethesda, MD 20892.

Closed: January 24, 2020.

Time: 12:10 p.m. to 1:10 p.m.

Agenda: Review of Grant Applications.

Place: National Institutes of Health, John E. Porter Neuroscience Research Center, Building 35A, Rooms 620/630, 35 Convent Drive, Bethesda, MD 20892.

Open: January 24, 2020.

Time: 1:10 p.m. to 4:00 p.m.

Agenda: Scientific Talks and NIH Program Updates.

Place: National Institutes of Health, John E. Porter Neuroscience Research Center, Building 35A, Rooms 620/630, 35 Convent Drive, Bethesda, MD 20892.

Contact Person: Franziska Grieder, D.V.M., Ph.D., Executive Secretary, Council of Councils Director, Office of Research Infrastructure Programs, Division of Program Coordination, Planning, and Strategic Initiatives, Office of the Director, NIH, 6701 Democracy Boulevard, Room 948, Bethesda, MD 20892, GriederF@mail.nih.gov, 301-435-0744.

Name of Committee: Council of Councils.

Open: May 15, 2020.

Time: 8:15 a.m. to 12:00 p.m.

Agenda: Call to Order and Introductions; Announcements and Updates; Scientific Talks; NIH Program Updates.

Place: National Institutes of Health, 6001 Executive Boulevard, Neuroscience Center, Room C, E, Bethesda, MD 20892.

Closed: May 15, 2020.

Time: 12:00 p.m. to 1:00 p.m.

Agenda: Review of Grant Applications.

Place: National Institutes of Health, 6001 Executive Boulevard, Neuroscience Center, Room C, E, Bethesda, MD 20892.

Open: May 15, 2020.

Time: 1:00 p.m. to 4:00 p.m.

Agenda: Scientific Talks and NIH Program Updates.

Place: National Institutes of Health, 6001 Executive Boulevard, Neuroscience Center, Room C, E, Bethesda, MD 20892.

Contact Person: Franziska Grieder, D.V.M., Ph.D., Executive Secretary, Council of Councils Director, Office of Research Infrastructure Programs, Division of Program Coordination, Planning, and Strategic Initiatives, Office of the Director, NIH, 6701 Democracy Boulevard, Room 948, Bethesda, MD 20892, GriederF@mail.nih.gov, 301-435-0744.

Name of Committee: Council of Councils.

Open: September 11, 2020.

Time: 8:15 a.m. to 12:00 p.m.

Agenda: Call to Order and Introductions; Announcements and Updates; Scientific Talks; NIH Program Updates.

Place: National Institutes of Health, Natcher Building, Building 45, Room D, C1/C2 and G1/G2, 45 Center Drive, Bethesda, MD 20892.

Closed: September 11, 2020.

Time: 12:00 p.m. to 1:00 p.m.

Agenda: Review of Grant Applications.

Place: National Institutes of Health, Natcher Building, Building 45, Room D, C1/